antivirals
-
FDA authorizes Merck antiviral, which joins Pfizer pill as oral option for Covid-19
Merck antiviral drug molnupiravir received emergency authorization, joining Pfizer’s Paxlovid as the only authorized oral antiviral drugs for treating Covid-19. Though the Merck and Pfizer antivirals appear to work against the omicron variant, FDA officials stressed that these drugs are authorized only for certain patients and they are not a substitute for vaccination.
-
Artificial Intelligence, BioPharma
AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D
Exscientia’s IPO and private placement raised $464 million to support its artificial intelligence-based approach to discovering and developing new drugs. In addition to partnerships with pharmaceutical companies, an alliance with the Bill & Melinda Gates Foundation is focused on developing antiviral drugs for future pandemics.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Assembly Bio drops hepatitis B drug after liver problems surface in clinical trial
Four patients dosed with an experimental Assembly Biosciences hepatitis B treatment developed high levels of liver enzymes, a sign of drug-induced liver toxicity. The biotech has decided to stop further work on that drug and focus instead on developing its other clinical-stage hepatitis B drugs.
-
Gilead in-licenses drugs for respiratory, sexually transmitted infections from Novartis
Gilead is in-licensing investigational molecules for influenza, rhinovirus and herpes. Novartis will receive an upfront payment and an additional $291 million in milestones.
-
Gilead Sciences to launch authorized generics of two hepatitis C drugs
The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 – less than one-third the branded drugs’ prices – to reflect discounts given to payers.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
